Cystic Fibrosis Canada advocates for meaningful improvements in access to medicines in Canada.
Please visit our access to medicines page if you would like to know more about our current advocacy priorities. For more information on individual modulators currently available in Canada please see our fact sheets for Trikafta, Symdeko, Orkambi and Kalydeco.
Our dedicated community and government relations team advocate directly with national and provincial government officials, drug system regulators, manufacturers and policy-makers.
AN URGENT PRIORITY
Today, a very high priority is to achieve access to the breakthrough medicine Trikafta, which is not currently available in Canada. With the potential to help up to 90% of people with CF, it represents the single biggest advancement in treating cystic fibrosis in the history of the disease.
Our CEO, Chief Scientific Officer, program team, volunteers and Board are pushing hard for three things:
- To get Trikafta submitted, fast-tracked and approved by Health Canada.
- To get public funding for all modulator drugs that are currently approved in Canada.
- To have a regulatory and reimbursement environment in Canada that does not unnecessarily limit our access to new life-saving therapies.
Please see a timeline of our efforts to date. Because #CFcantwait.
YOU CAN HELP!
We’ve assembled a toolkit of materials, tips and tools that you can use to make your voice heard. Because people living with CF can’t wait. #CFcantwait